CGC Stock Analysis: Buy, Sell, or Hold?
CGC - Canopy Growth Corporation Common Shares
$0.67
-0.01 (-1.00%)
▼
5d:
-9.54%
30d:
-28.88%
90d:
-25.13%
WAIT
LOW Confidence
Analysis Updated: Oct 22, 2026 12:00 AM ET
Earnings: Nov 06, 2026
13d
Get Alerted When CGC Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 MIXED SIGNALS: CGC shows conflicting indicators. Wait for confirmation before entering.
📊 MIXED SIGNALS: CGC shows conflicting indicators. Wait for confirmation before entering.
In-depth Analysis How we analyze
Valuation Analysis: CGC is currently trading at $0.67, which is considered oversold relative to its 30-day fair value range of $0.75 to $0.94. From a valuation perspective, the stock is trading at a discount (Forward PE: -2.6) compared to its historical average (13.0). At these levels, the market is pricing in 0% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, CGC is in a downtrend. The price is currently testing key support at $0.65. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: CGC scores 35/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $0.92 (+38.5%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, CGC is in a downtrend. The price is currently testing key support at $0.65. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: CGC scores 35/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $0.92 (+38.5%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$0.75 -
$0.94
Company Quality Score
44/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
61.9%
Protect Your Profits
Holding CGC? Use our AI-powered strategies to protect your downside while keeping your long-term position.
View Profit Protection PlanAll Signals
- BULLISH: Price oversold vs 30-day range
- BEARISH: Weak technical setup (35/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 38.5% below Wall St target ($0.92)
- BULLISH: Market expects only 0% annual growth - appears undervalued
- WARNING: Composite score 44/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$0.75 -
$0.94
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$0.65
Resistance Level
$0.86
Current Trend
Downtrend
Technical data as of
Oct 22, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-2.60
Wall Street Target
$0.92
(+38.5%)
Revenue Growth (YoY)
12.5%
Profit Margin
-79.2%
PE vs Historical
-2.6 vs 13.0
CHEAP
Share & Embed Analysis
Last updated: October 23, 2026 7:07 AM ET
Data refreshes hourly during market hours. Next update: 8:07 AM
Data refreshes hourly during market hours. Next update: 8:07 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is CGC showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Drug Manufacturers - Specialty & Generic Stocks
Top-rated stocks in Drug Manufacturers - Specialty & Generic by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NBIX
Neurocrine Biosciences I… |
STRONG BUY
29 analysts |
$207 | 60 HOLD |
|
ELAN
Elanco Animal Health |
STRONG BUY
16 analysts |
$31 | 49 HOLD |
|
ALKS
Alkermes Plc |
STRONG BUY
19 analysts |
$56 | 43 HOLD |
|
AQST
Aquestive Therapeutics I… |
STRONG BUY
9 analysts |
$9 | 62 BUY |
|
HROW
Harrow Health Inc |
STRONG BUY
9 analysts |
$65 | 59 HOLD |
Advanced CGC Option Strategies
Professional options setups generated by AI based on today's CGC price and gamma walls.
